Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics reported Q2 2026 consolidated revenue of KRW 1.32T and operating profit of KRW 586.4B, marking a year-over-year increase of 30.2% and 22.9%, respectively.
📊 [Key Disclosure Details & Financial Summary]
- Reporting Period:
- Current Period (Q2 2026): 2026-04-01 ~ 2026-06-30
- Previous Period (Q1 2026): 2026-01-01 ~ 2026-03-31
- Same Period Last Year (Q2 2025): 2025-04-01 ~ 2025-06-30
- Cumulative Current Period (H1 2026): 2026-01-01 ~ 2026-06-30
- Cumulative Same Period Last Year (H1 2025): 2025-01-01 ~ 2025-06-30
- Q2 2026 Preliminary Consolidated Performance:
- Revenue: KRW 1.32T / KRW 1,320.9B (+5.1% QoQ, +30.2% YoY)
- Operating Profit: KRW 586.4B (+1.0% QoQ, +22.9% YoY)
- Profit Before Income Tax: KRW 584.6B (-8.7% QoQ, +32.2% YoY)
- Net Profit: KRW 430.7B (-8.2% QoQ, +29.1% YoY)
- Net Profit Attributable to Owners of Parent: KRW 430.7B (-8.2% QoQ, +29.1% YoY)
- H1 2026 Cumulative Preliminary Consolidated Performance:
- Revenue: KRW 2.58T / KRW 2,578.0B (+28.0% YoY)
- Operating Profit: KRW 1.17T / KRW 1,167.2B (+28.6% YoY)
- Profit Before Income Tax: KRW 1.23T / KRW 1,225.2B (+39.0% YoY)
- Net Profit: KRW 899.9B (+35.3% YoY)
- Net Profit Attributable to Owners of Parent: KRW 899.9B (+35.3% YoY)
- Other Key Notes:
- Figures are preliminary and subject to change based on the external auditor’s review.
- Q2 2025 figures are based on the review report prior to reflecting discontinued operations profit/loss from Samsung Bioepis (KRW -9.2B for Q2 2025 and KRW 35.0B for H1 2025 cumulative) due to corporate spin-off.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of External Auditor’s Review and Final Figures
These figures are preliminary results prepared before the completion of the external auditor’s review. Checking the auditor’s opinion and finalized financial statements in the upcoming semi-annual report is important for identifying any discrepancies between preliminary and finalized figures. Details can be verified in the financial statements and external auditor’s review report section of the upcoming semi-annual report.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
